BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 28 March 2001 (28.03.01)	
International application No. PCT/GB00/02735	**Applicant's or agent's file reference** SAH01156WO
International filing date (day/month/year) 17 July 2000 (17.07.00)	**Priority date** (day/month/year) 16 July 1999 (16.07.99)
Applicant BARTLETT, Jeremy, Dennis	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

12 February 2001 (12.02.01)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Olivia TEFY
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
SAH01156WO		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 00/ 02735	17/07/2000	16/07/1999
Applicant		
BIOCOMPATIBLES LTD.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [ ] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [ ] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. 1

   [ ] as suggested by the applicant.

   [X] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [ ] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/02735

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

A radially self-expanding stent for implantation in a body passage comprises first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends which is mechanically biassed towards a first radially expanded configuration in which it is unconstrained by externally applied forces and can be retained in a second radially compressed configuration, and in which some of all of the filament ends at the ends of the body are fixed together in pairs each cosisting of counter-rotating filaments by placing the filaments over one another and placing them adjacent to and substantially parallel to one another and further comprising a join at each end fixing to retain the ends of the filaments in contact with one another.

INTERNATIONAL SEARCH REPORT

International Application No
PC[redacted]B 00/02735

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 16388 A (BOSTON SCIENT CORP) 8 April 1999 (1999-04-08) page 3, line 30 -page 4, line 12; claims 1-5; figures	1
A	WO 99 25271 A (SCHNEIDER EUROP GMBH ;PIERER WOLFGANG (DE); BURLAKOV OLEG AFANASEV) 27 May 1999 (1999-05-27) page 5, last paragraph; claims; figures	1
A	EP 0 744 164 A (COOK INC) 27 November 1996 (1996-11-27) claims; figures	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 October 2000	27/10/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Neumann, E

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 00/02735

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9916388 A	08-04-1999	US 6071308 A	06-06-2000
		EP 1018985 A	19-07-2000
WO 9925271 A	27-05-1999	DE 19750971 A	08-07-1999
		AU 1873599 A	07-06-1999
		EP 1032329 A	06-09-2000
EP 0744164 A	27-11-1996	AU 696197 B	03-09-1998
		AU 5240596 A	19-12-1996
		CA 2176987 A	26-11-1996
		JP 9099095 A	15-04-1997
		US 5707376 A	13-01-1998

PATENT COOPERATION TREATY

PCT

14

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
SAH01156WO		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB00/02735	17/07/2000	16/07/1999
International Patent Classification (IPC) or national classification and IPC A61F2/06		
Applicant BIOCOMPATIBLES LTD. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
12/02/2001	10.08.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Péru, L Telephone No. +49 89 2399 2377

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02735

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
Description, pages:

1-13 as originally filed

Claims, No.:

1-11 as originally filed

Drawings, sheets:

1/5-5/5 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item..

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-11
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-11
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-11
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

V. Novelty and inventive step

1 The document WO 99/25271 (**D1**) is regarded as being the closest prior art to the subject-matter of claim 1, and shows (Fig.1): a radially self-expanding stent for implantation in a body passage comprising first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends [...] and in which some or all of the filament ends at the ends of the body are fixed together in pairs, each consisting of counter-rotating filaments.

The subject-matter of claim 1 differs from this known stent in the design of the fixed ends of the filaments.
The subject-matter of claim 1 is therefore novel (Article 33.2 PCT).

2 The problem to be solved by the present invention may thus be regarded as providing an alternative design: In D1 (Fig.1), one of the ends is made by a continuous wire, the other one by twisted wires, other possibilities being disclosed (melting, gluing...: page 5, line last but 6).

The design defined in claim 1 is such that the filament ends are fixed by placing the filaments over one another and placing them adjacent to and substantially parallel to one another, wherein they moreover comprise a join at each end fixing to retain the ends of the filaments in contact with one another.

This was neither disclosed nor suggested by the available prior art documents, and would allow a better elastic deformation when the stent is put into place.
The subject-matter of claim 1 is thus considered as involving an inventive step (Article 33.3 PCT).

3 Claims 2-11 are dependent on claim 1 and as such also meet the requirements of the PCT with respect to novelty and inventive step.

VII. Other remarks

1 Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

2 Independent claims are not in the two-part form in accordance with Rule 6.3(b) PCT, which in the present case would be appropriate, with those features known in combination from the prior art (see part V) being placed in a preamble and with the remaining features being included in a characterising part.

3 The features of the claims are not provided with reference signs placed in parentheses (Rule 6.2(b) PCT).

4 According to the requirements of Rule 11.13(l) PCT, reference signs not appearing in the drawings shall not appear in the description. This requirement is not met in view of the reference sign (17) mentioned on page 12 line 27.

VIII. Clarity

1 The formulation of claim 1 makes it not clear what is intended to be defined: The use of the active form for the verb ("comprises") renders unclear whether all the features are part or not of the subject-matter of the claim.

2 Claim 3 is not clear due to the reference to the welding, which is not previously defined.
Claim 5 is not clear since it is in contradiction to claim 4 on which it depends.

3 Moreover, product claims 3 and 5 attempt to define their subject-matter by the process of manufacturing it. It is not clear what specific technical characteristics this process implies for the product itself and how the way of producing would restrict the device itself in terms of product features.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB 00/02735

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 16388 A (BOSTON SCIENT CORP) 8 April 1999 (1999-04-08) page 3, line 30 -page 4, line 12; claims 1-5; figures	1
A	WO 99 25271 A (SCHNEIDER EUROP GMBH ;PIERER WOLFGANG (DE); BURLAKOV OLEG AFANASEV) 27 May 1999 (1999-05-27) page 5, last paragraph; claims; figures	1
A	EP 0 744 164 A (COOK INC) 27 November 1996 (1996-11-27) claims; figures	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 October 2000	27/10/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Neumann, E

1

INTERNATIONAL SEARCH REPORT

Interna tal Application No
PCT/GB 00/02735

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9916388 A	08-04-1999	US 6071308 A	06-06-2000
		EP 1018985 A	19-07-2000
WO 9925271 A	27-05-1999	DE 19750971 A	08-07-1999
		AU 1873599 A	07-06-1999
		EP 1032329 A	06-09-2000
EP 0744164 A	27-11-1996	AU 696197 B	03-09-1998
		AU 5240596 A	19-12-1996
		CA 2176987 A	26-11-1996
		JP 9099095 A	15-04-1997
		US 5707376 A	13-01-1998

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

GILL JENNINGS & EVERY
Broadgate House
7 Eldon Street
London EC2M 7LH
GRANDE BRETAGNE

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing *(day/month/year)*	10.08.2001
Applicant's or agent's file reference SAH01156WO	**IMPORTANT NOTIFICATION**

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB00/02735	17/07/2000	16/07/1999

Applicant
BIOCOMPATIBLES LTD. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Edel, M Tel.+49 89 2399-2426

Form PCT/IPEA/416 (July 1992)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
SAH01156WO		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/GB00/02735	17/07/2000	16/07/1999
International Patent Classification (IPC) or national classification and IPC A61F2/06		
Applicant BIOCOMPATIBLES LTD. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
12/02/2001	10.08.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Péru, L Telephone No. +49 89 2399 2377

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02735

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
Description, pages:

1-13 as originally filed

Claims, No.:

1-11 as originally filed

Drawings, sheets:

1/5-5/5 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-11
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-11
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-11
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

V. Novelty and inventive step

1 The document WO 99/25271 (D1) is regarded as being the closest prior art to the subject-matter of claim 1, and shows (Fig.1): a radially self-expanding stent for implantation in a body passage comprising first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends [...] and in which some or all of the filament ends at the ends of the body are fixed together in pairs, each consisting of counter-rotating filaments.

The subject-matter of claim 1 differs from this known stent in the design of the fixed ends of the filaments.
The subject-matter of claim 1 is therefore novel (Article 33.2 PCT).

2 The problem to be solved by the present invention may thus be regarded as providing an alternative design: In D1 (Fig.1), one of the ends is made by a continuous wire, the other one by twisted wires, other possibilities being disclosed (melting, gluing...: page 5, line last but 6).

The design defined in claim 1 is such that the filament ends are fixed by placing the filaments over one another and placing them adjacent to and substantially parallel to one another, wherein they moreover comprise a join at each end fixing to retain the ends of the filaments in contact with one another.

This was neither disclosed nor suggested by the available prior art documents, and would allow a better elastic deformation when the stent is put into place.
The subject-matter of claim 1 is thus considered as involving an inventive step (Article 33.3 PCT).

3 Claims 2-11 are dependent on claim 1 and as such also meet the requirements of the PCT with respect to novelty and inventive step.

VII. Other remarks

1 Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the document D1 is not mentioned in the description, nor is this document identified therein.

2 Independent claims are not in the two-part form in accordance with Rule 6.3(b) PCT, which in the present case would be appropriate, with those features known in combination from the prior art (see part V) being placed in a preamble and with the remaining features being included in a characterising part.

3 The features of the claims are not provided with reference signs placed in parentheses (Rule 6.2(b) PCT).

4 According to the requirements of Rule 11.13(l) PCT, reference signs not appearing in the drawings shall not appear in the description. This requirement is not met in view of the reference sign (17) mentioned on page 12 line 27.

VIII. Clarity

1 The formulation of claim 1 makes it not clear what is intended to be defined: The use of the active form for the verb ("comprises") renders unclear whether all the features are part or not of the subject-matter of the claim.

2 Claim 3 is not clear due to the reference to the welding, which is not previously defined.
Claim 5 is not clear since it is in contradiction to claim 4 on which it depends.

3 Moreover, product claims 3 and 5 attempt to define their subject-matter by the process of manufacturing it. It is not clear what specific technical characteristics this process implies for the product itself and how the way of producing would restrict the device itself in terms of product features.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05331 A1

(51) International Patent Classification[7]: A61F 2/06

(21) International Application Number: PCT/GB00/02735

(22) International Filing Date: 17 July 2000 (17.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9916812.2 16 July 1999 (16.07.1999) GB
0013362.9 1 June 2000 (01.06.2000) GB

(71) Applicant *(for all designated States except US)*: **BIO-COMPATIBLES LTD** [GB/GB]; Frensham House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **BARTLETT, Jeremy, Dennis** [GB/GB]; Biocompatibles Ltd., Frensham House, Farnham Business Park, Weydon Lane, Farnham, Surrey GU9 8QL (GB).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BRAIDED STENT



(57) Abstract: A radially self-expanding stent for implantation in a body passage comprises first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends which is mechanically biassed towards a first radially expanded configuration in which it is unconstrained by externally applied forces and can be retained in a second radially compressed configuration, and in which some or all of the filaments ends at the ends of the body are fixed together in pairs each consisting of counter-rotating filaments by placing the filaments over one another and placing them adjacent to and substantially parallel to one another and further comprising a join at each end fixing to retain the ends of the filaments in contact with one another.

WO 01/05331 A1

BRAIDED STENT

The present invention relates to an implantable stent for transluminal implantation in a body lumen, especially found in peripheral and coronary blood vessels, but also for use in the colon, bile ducts, urethras or ileums.

There are several designs of stents, permanently implantable devices, for transluminal insertion into blood vessels and other lumen to prevent or reverse occlusion or stenosis thereof. There are three basic categories of device, namely heat-expandable devices, balloon-expandable devices and self-expanding devices. The present invention is concerned with self-expanding devices with an optional heat expanding capability, that is which are inserted into the body lumen in a radially compressed condition and which are mechanically biased towards a radially expanded position. Upon being released in the blood vessel at the desired position, the stent expands radially exerting outwardly directed pressure upon the inner surface of the wall of the body lumen in which it is positioned.

One such expanding device which is commercially available is the so-called Wallstent. The device is described in WO-A-83/03752. It consists of two sets of counter-rotating helical filaments of metallic wire which are braided together in a one over/one under pattern.

A difficulty with braided stents in general is the tendency of the filaments at the end of the stent to unravel and splay outwards before or after deployment. This tendency makes the stent difficult to handle and the splayed ends can damage the inside wall of the body vessel in which the stent is deployed. In WO-A-83/03752, it is suggested that the filaments may be joined to one another at the end of the stent. However, as explained in a later specification by Wallsten et al in US-A-5061275, for stents with a high axial braid angle α between counter-rotating filaments, that this rigidifies the ends of the prosthesis and can create unwanted permanent plastic deformation at

the joins when stent diameter is changed. This makes it difficult for the stent to freely and reversibly adopt differing diameters.

A new radially self-expanding stent according to a first aspect of the invention adapted for implantation in a body passage comprises first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends which is mechanically biased towards a first radially expanded configuration in which it is unconstrained by externally applied forces and can be retained in a second radially compressed configuration, and in which some or all of the filaments at the ends of the body are fixed together in pairs each consisting of counter-rotating filaments by placing the filament ends over one another and placing them adjacent to and substantially parallel to one another and further comprising a join at each end fixing to retain the ends of the filaments in contact with one another.

A stent with this configuration allows its ends to deform elastically during compression and expansion. The stress created during this process is redistributed over the section of the braid that is adjacent to a joined end and this deforms in a generally elastic manner. Because of this the join has a reduced stress load on it and can recover elastically.

In this case the respective filaments may be shaped such that the ends bend outward radially, and may be configured such that the angle at which they bend outward radially increases towards the end.

The filaments may be folded over one another or partially unfolded at the ends. The fixed ends may be shaped or heat treated to urge the respective filaments to a position in which they are biased out of parallel alignment with the adjacent filament to which they are connected at the region of the join.

Although the welding can be by resistance welding and/or by pressure, it is preferred for heat to be used,

generally by spot, laser, or plasma welding. Preferably the welding softens the metal such that it forms a globule before resolidifying to form a bead.

For some embodiments and applications it may be adequate to join some but not all of the filament ends. For instance it may be convenient to weld every third pair of counter-rotating filaments at the end of one or both ends of the stent body. Preferably at least every other pair is welded at both ends, more preferably every pair is welded at one, or preferably both, ends. In any of these cases each filament and may be joined to one of its next-but-one neighbours.

Preferably no filler wire is used in the welding although it may, for some purposes, be useful to include filler wire, for instance where the filler has different, usually greater, radiopacity than the material from which the metal filaments are made. The formation of a bead and/or the use of high radiopacity filler material at the join enables the ends of the stent to be made more radiopaque (to X-rays transmitted perpendicular to the axis) than the body of the stent between the ends. This assists in visualisation of the stent during an operation.

If a bead is formed it generally may have a diameter of at least 1.2 times that of the diameter of the filament, for instance at least 1.5 times or as much as or more than 2 times the diameter. The diameter of the bead is usually no more than 3, preferably less than 2.5, times the diameter of the filament. We have found that it assists retention of the stent on a delivery device and its delivery from that device if the bead's periphery extends outwardly beyond the periphery of the stent as defined by the filament surfaces, preferably on the inner wall. This results in the bead providing shoulders on either or both the inner and outer walls which can provide a radially directed surface against which a corresponding radially directed surface on a movable component of a delivery device can bear to impose motion of the stent relative to

other components of the delivery device. Preferably each bead provides a shoulder in a rearward (with respect to delivery) axial direction. The shape of the resolidified bead at least on the outer wall of the stent is generally rounded, for instance approximately elliptical, and this provides a smooth external stent surface to minimise damage to the inside wall of the vessel in which the stent is implanted and/or the delivery system in which the stent is placed prior to deployment.

A smooth inner weld surface is also preferable to ensure that the stent does not damage any device on which it is retained or any other mechanical device that may have to pass through it.

It is suitable for heat treatment to be conducted by subjecting the stent either before or after the welding operation to elevated temperatures to harden the metal. For Elgiloy, (available from Fort Wayne Metals) for instance, heat treatment, optionally in a vacuum or inert atmosphere, may be carried out at a temperature in the range 510 to 530°C, for instance around 520°C for a period of at least 2 hours, preferably about 3 hours.

The first radially expanded diameter is the diameter adopted by the stent when no externally directed force is exerted upon it, that is when it expands freely in air. This diameter is somewhat greater than the internal diameter of the lumen into which stent is to be implanted since this results in the stent exerting a continuous outwardly directed force on the internal wall of the body lumen in which it is located. In this fully unloaded conformation it is preferable that the angle α between filaments is less than 90°. Preferably in the range 70-89°, most preferably in the range 80° to 89°.

Preferably the mutual angle at which the filaments are fixed is in the range 0° to 15°.

The metallic stent is generally provided with a biocompatible coating, in order to minimise adverse interaction with the walls of the body vessel and/or with

the liquid, usually blood, flowing through the vessel. The coating may also allow delivery of a drug. The coating is preferably a polymeric material, which is generally provided by applying to the stent a solution or dispersion of preformed polymer in a solvent and removing the solvent. Non-polymeric coating materials may alternatively be used. Suitable coating materials, for instance polymers, may be polytetrafluoroethylene or silicone rubbers, or polyurethanes which are known to be biocompatible. Preferably however the polymer has zwitterionic pendant groups, generally ammonium phosphate ester groups, for instance phosphoryl choline groups or analogues thereof. Examples of suitable polymers are described in our earlier application number WO-A-93/01221. Particularly suitable polymers described in that specification are those which are cross-linkable after coating, since these remain stably adhered to the surface. We have described other suitable biocompatible coating polymers which may be used in WO-A-98/30615. Polymers as described in those specifications are hemo-compatible as well as generally biocompatible and, in addition, may be lubricious.

It is important to ensure that the metallic surfaces of the stent are completely coated in order to minimise unfavourable interactions, for instance with blood, which might lead to thrombosis in cases where this is not desirable. Although it may be possible to avoid the exposure to blood or metal surfaces at the crossover points, on the mutually contacting portions of the filaments, by sheathing the entire crossover points and hence fixing the filament to one another, as described in DE-A-4240177, it is preferred that the crossover points along the body of the stent should not be fixed to one another but should be allowed to move, for instance to slide or rotate relative to one another. It is thus preferred for the coating to cover entirely the wires even at the crossover points. This can be achieved by suitable

selection of coating conditions, such as coating solution viscosity, coating technique and/or solvent removal step.

It is preferred that each filament of the stent should execute at least one full turn of the helix. If the filaments execute less than a full turn, even with the joining of the ends of the filaments, the stent may be relatively unstable. Preferably each filament executes at least 6 turns, though generally less than 12 turns. It is preferred that the stent be formed from at least 4, more preferably at least 8 and most preferably at least 12 filaments in each direction. The number of filaments depends at least in part upon the diameter of each filament as well as the desired diameter and the desired size of the openings between the filaments of the stent in its radially expanded and contracted condition. The number of filaments and their diameter affects the flexibility of the stent in its radially contracted condition during delivery. Generally the number of filaments in each direction is 32 or less and more preferably from 24 downwards.

The filaments may be made from circular section wire. It may, alternatively be advantageous for rectangular section wire to be used, for instance as described in DE-A-4240177 and in the early Wallsten patent WO-A-83/03752. The use of flat (rectangular section wire) may provide optimum radial strength characteristics whilst minimising the overall thickness of the stent, especially at the crossover points, thereby minimising any interference of the liquid flow in the body passageway. The area of contact between wires at the crossover points can be maximised, if required, by the use of flat wire which increases the amount of friction between the wires upon relative movement, for instance during any changes in radius. This should increase the resistance of the expanded stent to radial contraction in use. The use of oval wire (with the smaller dimension being arranged substantially radially with respect to the stent axis) may

provide a particularly advantageous combination of strength whilst minimising the contact area at crossover points.

The braiding is usually in a one over-one under pattern although other patterns such as one under-two over or two under-two over could be used.

The thickness of the filaments depends upon the desired final diameter (open diameter) of the stent. Wire having a diameter of 0.04 mm upwards, for instance up to 0.20 mm may be used. Wire with diameters at the lower end of the range would generally be used for making stents for use in small blood vessels, for instance in coronary arteries, where the diameters of the stents is generally in the range 0.5 mm up to 4.0 mm (fully radially expanded diameter). Larger stents may be used in peripheral blood vessels, aortic aneurisms or in stents for use in urological passageways, the oesophagus and in the bile duct, where the stent may have a diameter up to about 30 mm.

The length of the stent in the fully unloaded conformation may be in the range 10 to 500 mm. The length depends on the intended application of the stent. For instance in peripheral arteries the stent may have a length for instance, in the range 40 to 300 mm. For coronary arteries, the length may be in the range 10 to 50 mm. The diameter may be in the range 2 to 4.5mm.

For most of the passageways, the diameter of the stents in the first radially expanded conformation is substantially constant along the length of the stent. The stent may flare or have a reduced diameter towards the end portion, in some instances. However, for an insertion into some body passages it may be preferred for the diameter, that is the cross-sectional area, to vary along the length of the stent. For instance it may reduce migration of a device by providing it with a varying diameter along its length such that increased diameter sections and/or reduced diameter sections locate at and interact with, respectively, increased diameter body passageways (for

instance openings into a higher volume organ) or reduced diameter sections, for instance at a sphincter. Such varying diameter portions may be provided by use of an appropriate braiding mandrel, or alternatively by a post-braiding heat treatment, changing braid angle during manufacture, or by provision of shaped restraining means such as non-helical filaments etc. Alternatively two or more stent segments may be fitted together for instance by welding two independently formed sections having the desired shape. One particular application of a varying diameter stent is a stent for use in urological passageways, for instance to overcome benign prostatic hyperplasia.

The filaments from which the braided stents are made are formed of a metal, for instance a surgical steel, and is usually of a type having good elastic properties, for instance a high cobalt stainless steel or an alloy such an Elgiloy. These such materials give a stent having good self-expanding capability.

In addition to the self-expanding capability of the stent, it may be provided with a temperature dependent mechanical characteristic which allows a mechanical property of the stent to be changed by heating the stent from a temperature below transition temperature to above transition temperature. Thus some or all of the filaments may be formed from a shape memory alloy material such as nitinol. In such cases, in the stent prior to implantation, the stent is at a temperature below the transition temperature at which the metal changes from the martensitic structure to the austenitic structure. The filaments are adapted such that a transition from below the transition temperature to above the transition temperature will result in the stent either adopting a radially further expanded configuration or, preferably, retaining the same shape but having an increased resistance to radial collapsing under inwardly exerted pressure.

The stent could also be included in a graft used to replace damaged blood vessels (aneurisms). For instance a stent according to the invention could be surrounded by a sleeve, of a porous or non-porous, elastic or inelastic, material. In this case, the sleeve may be configured so that it is able to deliver a drug to the tissue surrounding the stent when in use. Alternatively a sleeve could include one stent at each end, secured for instance by suturing or other means, to the stent. The stent can be sterilised before use using standard techniques.

The present invention is illustrated further in the accompanying figures in which:

Figure 1 is a side view of a stent according to the present invention in relaxed, radially expanded condition;

Figure 2 shows the minimum path of one filament in the stent of a first aspect of the invention;

Figure 3 shows a view of a filament join in an example of the present invention, together with a prior art joining arrangement;

Figure 4 is data showing the particular benefits of the invention as opposed to an alternative technique;

Figure 5 is a diagram showing a stent according to the invention during its construction; and

Figure 6 shows a view of a further example filament join possible in a stent according to the present invention.

As shown in figure 1, a stent 1 is formed of twelve wire filaments 2 arranged in right handed helices and twelve filaments 3 arranged in left handed helices. The filaments are braided in a one over/one under pattern. The angle α between the filaments in the radially expanded (relaxed, unloaded) condition is generally in the range 60-90°, in this example in the range 80-90°. Each filament, as shown more clearly in figure 2 which is enlarged relative to Figure 1, executes just over one complete turn (about 1¼ turns) within the length L of the stent. Each turn of the helix has a pitch of l_1. The diameter of the

stent, and of each helix is d_1. In the radially compressed condition and axially extended condition, the length L increases to L_2, whilst the pitch of each helix increases from l_1 to l_2 and the diameter reduces from d_1 to d_2. The dotted line in figure 2 shows a portion of the filament 2 in its radially compressed state and indicates the length of one half of a turn of the helix as $l_2/2$.

Reverting to figure 1, at the ends 4 and 5 of the stent a pair of counter-rotating helices are connected together by overlapping them and laying them substantially parallel to one another and forming a bead of metal 8 formed by welding or fusing the wires 6 and 7. The angle β on the tangential plane on the surface of the body between the filaments 6 and 7 is, in this embodiment, about $10° \pm 5°$. With the angle β selected as illustrated, in the fully unloaded condition, the ends of the stent do not flare to a disadvantageous degree.

The stent illustrated in figure 1 is, for instance, suitable for implanting in a coronary artery. The diameter d_1 is in the range 2.5-4.0 mm. The diameter d_2 of the stent, in its axially compressed condition is generally at least $\frac{1}{3}$ less than diameter d_1, and for instance in the range 0.5 to 2.0mm. The wire used to form the filaments has a circular section and a diameter of 0.09 mm. The wire is formed from a high cobalt stainless steel or alloy such as Elgiloy. The beads 8 include no filler material but consist only of the material from which the wire of the filaments is formed. The beads generally have a diameter in the range 0.18 to 0.22 mm. When visualised using X-rays, the end portions of the stent including the beads 8 have an increased radiopacity compared to the body of the stent.

The length of the stent in this condition is L_2 (not shown), whilst its diameter is d_2. The angle α_2 between the filaments is reduced by 10 to 60% of the original angle. The stent can be retained in this condition either by exerting radial inwardly directed forces from the stent

along its length, or by exerting axially outwardly directed forces at the ends of the stent. The fixing of the ends of the filaments according to the present invention render this latter means of retaining the stent in its radially compressed condition more convenient since it can be achieved by extending pins or other means between the filaments adjacent to the bead 8, or beyond the first crossover points along the length of the stent, at each end and increasing the separation between the ends to extend to the stent in the axial direction. Furthermore, the stent is easier to load into a delivery device.

As well as making it convenient to extend the stent, and stabilise it against flaring at the ends, the joining of the ends of the filaments allows the stent further to be axially compressed by exerting axially inwardly directed pressure against each end, so as to expand the radius of the stent, especially in its central portion, beyond the diameter d_1. The stent can thus be used to exert radially outwardly forces at a greater radial distance from the axis (than d_1) inside the blood vessel, for instance adding to or replacing the step of balloon dilatation prior to stent deployment.

Figures 3 and 6 show two alternative joints that may be employed in the present invention. Referring first to figure 3, in this example the filaments 3 are joined with a weld which forms a bead 8 and are splayed slightly with a constant angle. Referring to figure 6, in this example the join 8 is also formed by a weld, but no bead is formed.

As can be seen from figure 6, the joins 8 extend outward radially from the main body of the stent 1, and the filaments 3 are shaped so that the angle at which the join 8 bends outward increases (preferably by 10 to 15°) as the filaments extend towards the join 8.

It has been shown that the particular overlap and alignment configuration of the join has, surprisingly, particular benefits, in terms of strength and flexibility, over other arrangements, such as a simple twisting

arrangement. Data to this effect is shown in figure 4, which compares the prior art twist design 2 with an example of the invention.

Without the joining of the filament ends such a test might be completely impossible and, even if it were not, the stent ends would be damaged during such an operation. With the angle α being less than 90°, the use of the stent as a dilation device is convenient since a relatively large increase in diameter can be achieved with a relatively small axial reduction in length (as compared to a stent with a higher value of α).

The manufacture of the stent will now be described with reference to figures 5A to 5E. This example differs slightly from that shown in figure 3, as the filaments have a differing cross-over configuration near their join.

Firstly, filaments 2, 3 are braided together around a mandrel (not shown) to produce a generally tubular structure. The filaments 2, 3 are wound to satisfy the braid angle requirements discussed above, and the number of filaments selected dependent upon the overall diameter of the stent that is required, as well as the particular application in which the stent is to be used.

Once secured, the filaments 2, 3 are severed around the circumference at position 16, which is located adjacent a series of crossover points. With the filaments secured at 15 and, though not shown, at the other, leading end of the stent portion 17, the stent can be removed from the forming mandrel and heat treated and/or coated as required.

As part of the heat treatment, or even prior to or after heat treatment and coating the ends of some or all of the next-but-one neighbouring filaments are bent and aligned parallel to one another in a manner shown in figure 5B. Also as part of this process the orientation of the cross-over point adjacent to the ends has its orientation changed in the manner shown in figure 5C. Some or all of the aligned ends are then welded together. The weld may be

such that beads 8 are formed, although beads 8 do not need to be formed on each end.

After this step, the stent can be cleaned and coated with a solution of a 1:2 (mole) copolymer of (methacryloyloxy ethyl)-2-(trimethylammonium ethyl) phosphate inner salt with lauryl methacrylate in ethanol (as described in example 2 of WO-A-93/01221) for example.

CLAIMS

1. A radially self-expanding stent for implantation in a body passage comprises first and second sets of mutually counter-rotating metallic filaments which are braided together and define a tubular stent body having two ends which is mechanically biassed towards a first radially expanded configuration in which it is unconstrained by externally applied forces and can be retained in a second radially compressed configuration, and in which some or all of the filament ends at the ends of the body are fixed together in pairs each consisting of counter-rotating filaments by placing the filaments over one another and placing them adjacent to and substantially parallel to one another and further comprising a join at each end fixing to retain the ends of the filaments in contact with one another.

2. A stent according to claim 1, wherein the fixed ends are shaped or heat treated to urge the respective filaments to a position in which they are biased out of alignment with the adjacent filament to which they are connected and cross over one another.

3. A stent according to claim 1 or claim 2, wherein the welding softens the metal such that it forms a globule before resolidifying to form a bead.

4. A stent according to any preceding claim, wherein each filament end is welded to one of its next-but-one neighbours.

5. A stent according to claim 1, 2, 3 or 4, wherein some but not all of the filament ends are welded.

6. A stent according to claim 5, wherein the join generally has a diameter of at least 1.2 times that of the diameter of the filament.

7. A stent according to claim 5 or 6, wherein the diameter of the join is no more than 3, preferably less than 2.5, times the diameter of the filament.

8. A stent according to any of claim 5 to 7, wherein at least some of the joins provide a shoulder in a rearward axial direction.

9. A stent according to any preceding claim, wherein, in its fully unloaded conformation the angle α between filaments is less than 90°.

10. A stent according to any preceding claim, wherein the angle at which the filaments are joined to one another is in the range 0° to 15°.

11. A stent according to any preceding claim, wherein the filaments bend outwardly towards the join, the angle at which they bend increasing as the filaments extend towards the join.



FIG 1



FIG 2

PRIOR ART



FIG 3



FIGURE 4

PRIOR ART	SAMPLE ID	CYCLES	FAILURE MODE
Twisted Wire Design	593BB/129/001	1700	Wire Broken off completely
	593BB/129/002	2700	1 Welded Bead Mising
	593BB/129/003	876	Broken Wire at Twist
	593BB/129/004	118	Twisted end broken off completely
	593BB/129/005	42	Twisted end broken off completely
	Average	**1087**	
	SD	1124	
Stent Design 2 Invention	190BB/103/21	3000	Pass
	190BB/103/22	3000	Pass
	190BB/103/23	3000	Pass
	190BB/103/24	2600	Wire Broken at weld
	190BB/103/25	1900	Wire Broken at weld (between 1900 and 2000)
	Average	2700	
	SD	480	
	t-test prob. P	0.03	Significant difference in 2 tailed t test


5A
5B
5C
5D
5E
16
15
8
3
2
CARDIO-0061-A



FIG 6

INTERNATIONAL SEARCH REPORT

Intern ıal Application No
PCT/GB 00/02735

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 16388 A (BOSTON SCIENT CORP) 8 April 1999 (1999-04-08) page 3, line 30 -page 4, line 12; claims 1-5; figures	1
A	WO 99 25271 A (SCHNEIDER EUROP GMBH ;PIERER WOLFGANG (DE); BURLAKOV OLEG AFANASEV) 27 May 1999 (1999-05-27) page 5, last paragraph; claims; figures	1
A	EP 0 744 164 A (COOK INC) 27 November 1996 (1996-11-27) claims; figures	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 October 2000	27/10/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Neumann, E

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern ıal Application No
PCT/GB 00/02735

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9916388 A	08-04-1999	US 6071308 A	06-06-2000
		EP 1018985 A	19-07-2000
WO 9925271 A	27-05-1999	DE 19750971 A	08-07-1999
		AU 1873599 A	07-06-1999
		EP 1032329 A	06-09-2000
EP 0744164 A	27-11-1996	AU 696197 B	03-09-1998
		AU 5240596 A	19-12-1996
		CA 2176987 A	26-11-1996
		JP 9099095 A	15-04-1997
		US 5707376 A	13-01-1998